Mechanisms of Topoisomerase I (TOP1) Gene Copy Number Increase in a Stage III Colorectal Cancer Patient Cohort

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Smith, David Hersi ^a,b   Christensen, Ib Jarle ^c   Jensen, Niels Frank ^b   Markussen, Bo ^d   Rømer, Maria Unni ^b   Nygård, Sune Boris ^b   Müller, Sven ^a   Nielsen, Hans Jørgen ^b,e   Brünner, Nils ^b   van Nielsen, Kirsteng ^a  

^a AGILENT TECHNOLOGIES   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE;

ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CENTROMERE; CHROMOSOME 2; CHROMOSOME 20Q; COLORECTAL CANCER; CONTROLLED STUDY; COPY NUMBER VARIATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; GENE FREQUENCY; GENE FUNCTION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; METAPHASE; ONCOGENE; OVERALL SURVIVAL; PLOIDY; TOP1 GENE;

CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 2; CHROMOSOMES, HUMAN, PAIR 20; COHORT STUDIES; COLORECTAL NEOPLASMS; DNA TOPOISOMERASES, TYPE I; FEMALE; GENE DOSAGE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS;

EID: 84875931600     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060613     Document Type: Article

References (39)

1. Siegel R, Ward E, Brawley O, Jemal A, (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236. caac.20121 [pii];10.3322/caac.20121 [doi].
2. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, et al. (2005) Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23: 4866-4875. JCO.2005.07.113 [pii];10.1200/JCO.2005.07.113 [doi].
3. Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, et al. (2007) Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 370: 143-152. S0140-6736(07)61087-3 [pii];10.1016/S0140-6736(07)61087-3 [doi].
4. Tournigand C, Andre T, AchilleE, Lledo G, Flesh M, et al. (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22: 229-237. 10.1200/JCO.2004.05.113 [doi];JCO.2004.05.113 [pii].
5. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, et al. (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23-30. 10.1200/JCO.2004.09.046 [doi];JCO.2004.09.046 [pii].
6. Hsiang YH, Liu LF, (1988) Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48: 1722-1726.
7. Pommier Y, (2009) DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem Rev 109: 2894-2902. 10.1021/cr900097c [doi].
8. Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, et al. (2008) Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 26: 2690-2698. 26/16/2690 [pii];10.1200/JCO.2007.15.5580 [doi].
9. Koopman M, Knijn N, Richman S, Seymour M, Quirke P, et al. (2009) The correlation between Topoisomerase-I (Topo1) expression and outcome of treatment with capecitabine and irinotecan in advanced colorectal cancer (ACC) patients (pts) treated in the CAIRO study of the Dutch Colorectal Cancer Group (DCCG). Eur J Cancer Suppl 7: 321.
10. Hermsen M, Postma C, Baak J, Weiss M, Rapallo A, et al. (2002) Colorectal adenoma to carcinoma progression follows multiple pathways of chromosomal instability. Gastroenterology 123: 1109-1119. S0016508502002160 [pii].
11. Carvalho B, Postma C, Mongera S, Hopmans E, Diskin S, et al. (2009) Multiple putative oncogenes at the chromosome 20q amplicon contribute to colorectal adenoma to carcinoma progression. Gut 58: 79-89. gut.2007.143065 [pii];10.1136/gut.2007.143065 [doi].
12. Meijer GA, Hermsen MA, Baak JP, van Diest PJ, Meuwissen SG, et al. (1998) Progression from colorectal adenoma to carcinoma is associated with non-random chromosomal gains as detected by comparative genomic hybridisation. J Clin Pathol 51: 901-909.
13. Hirsch D, Camps J, Varma S, Kemmerling R, Stapleton M, et al. (2012) A new whole genome amplification method for studying clonal evolution patterns in malignant colorectal polyps. Genes Chromosomes Cancer 51: 490-500. 10.1002/gcc.21937 [doi].
14. Romer MU, Jensen NF, Nielsen SL, Muller S, Nielsen KV, et al. (2012) TOP1 gene copy numbers in colorectal cancer samples and cell lines and their association to in vitro drug sensitivity. Scand J Gastroenterol 47: 68-79. 10.3109/00365521.2011.638393 [doi].
15. Romer MU, Nygard SB, Christensen IJ, Nielsen SL, Nielsen KV, et al. (2012) Topoisomerase 1(TOP1) gene copy number in stage III colorectal cancer patients and its relation to prognosis. Mol Oncol. S1574-7891(12)00093-2 [pii];10.1016/j.molonc.2012.09.001 [doi].
16. Nielsen HJ, McArdle C, Moesgaard F, The RANX05 Study Group (1998) The effect of ranitidine on long-term survival on primary colorectal cancer. A 40 months interim analysis. GI Cancer pp. 227-233.
17. Matthiesen SH, Hansen CM, (2012) Fast and Non-Toxic In Situ Hybridization without Blocking of Repetitive Sequences. PLoS One 7: e40675. 10.1371/journal.pone.0040675 [doi];PONE-D-12-07283 [pii].
18. Nielsen KV, Ejlertsen B, Moller S, Jensen MB, Balslev E, et al. (2012) Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status. Mol Oncol 6: 88-97. S1574-7891(11)00142-6 [pii];10.1016/j.molonc.2011.11.006 [doi].
19. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, et al. (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118-145. JCO.2006.09.2775 [pii];10.1200/JCO.2006.09.2775 [doi].
20. Boonsong A, Marsh S, Rooney PH, Stevenson DA, Cassidy J, et al. (2000) Characterization of the topoisomerase I locus in human colorectal cancer. Cancer Genet Cytogenet 121: 56-60. S0165-4608(00)00242-9 [pii].
21. Myllykangas S, Knuutila S, (2006) Manifestation, mechanisms and mysteries of gene amplifications. Cancer Lett 232: 79-89. S0304-3835(05)00827-X [pii]; 10.1016/j.canlet.2005.07.045 [doi].
22. Albertson DG, Collins C, McCormick F, Gray JW, (2003) Chromosome aberrations in solid tumors. Nat Genet 34: 369-376. 10.1038/ng1215 [doi];ng1215 [pii].
23. Albertson DG, (2006) Gene amplification in cancer. Trends Genet 22: 447-455. S0168-9525(06)00175-2 [pii];10.1016/j.tig.2006.06.007 [doi].
24. Lengauer C, Kinzler KW, Vogelstein B, (1998) Genetic instabilities in human cancers. Nature 396: 643-649. 10.1038/25292 [doi].
25. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, et al. (2010) The landscape of somatic copy-number alteration across human cancers. Nature 463: 899-905. nature08822 [pii];10.1038/nature08822 [doi].
26. Ryan D, Rafferty M, Hegarty S, O'Leary P, Faller W, et al. (2010) Topoisomerase I amplification in melanoma is associated with more advanced tumours and poor prognosis. Pigment Cell Melanoma Res23: 542-553. PCR720 [pii];10.1111/j.1755-148X.2010.00720.x [doi].
27. Fan B, Dachrut S, Coral H, Yuen ST, Chu KM, et al. (2012) Integration of DNA copy number alterations and transcriptional expression analysis in human gastric cancer. PLoS One 7: e29824. 10.1371/journal.pone.0029824 [doi];PONE-D-11-18525 [pii].
28. Ried T, Knutzen R, Steinbeck R, Blegen H, Schrock E, et al. (1996) AID-GCC5>3.0.CO;2-2 [pii]; 10.1002/(SICI)1098-2264(199604)15:4<234::AID-GCC5>3.0.CO;2-2 [doi].
29. Rooney PH, Boonsong A, McKay JA, Marsh S, Stevenson DA, et al. (2001) Colorectal cancer genomics: evidence for multiple genotypes which influence survival. Br J Cancer 85: 1492-1498. 10.1054/bjoc.2001.2095 [doi];S0007092001920956 [pii].
30. Korn WM, Yasutake T, Kuo WL, Warren RS, Collins C, et al. (1999) AID-GCC2>3.0.CO;2-6 [pii].
31. Tsafrir D, Bacolod M, Selvanayagam Z, Tsafrir I, Shia J, et al. (2006) Relationship of gene expression and chromosomal abnormalities in colorectal cancer. Cancer Res 66: 2129-2137. 66/4/2129 [pii];10.1158/0008-5472.CAN-05-2569 [doi].
32. Jones AM, Douglas EJ, Halford SE, Fiegler H, Gorman PA, et al. (2005) Array-CGH analysis of microsatellite-stable, near-diploid bowel cancers and comparison with other types of colorectal carcinoma. Oncogene 24: 118-129. 1208194 [pii];10.1038/sj.onc.1208194 [doi].
33. De Angelis PM, Clausen OP, Schjolberg A, Stokke T, (1999) Chromosomal gains and losses in primary colorectal carcinomas detected by CGH and their associations with tumour DNA ploidy, genotypes and phenotypes. Br J Cancer 80: 526-535. 10.1038/sj.bjc.6690388 [doi].
34. Tabach Y, Kogan-Sakin I, Buganim Y, Solomon H, Goldfinger N, et al. (2011) Amplification of the 20q chromosomal arm occurs early in tumorigenic transformation and may initiate cancer. PLoS One 6: e14632. 10.1371/journal.pone.0014632 [doi].
35. Dyrso T, Li J, Wang K, Lindebjerg J, Kolvraa S, et al. (2011) Identification of chromosome aberrations in sporadic microsatellite stable and unstable colorectal cancers using array comparative genomic hybridization. Cancer Genet 204: 84-95. S0165-4608(10)00482-6 [pii];10.1016/j.cancergencyto.2010.08.019 [doi].
36. Lassmann S, Weis R, Makowiec F, Roth J, Danciu M, et al. (2007) Array CGH identifies distinct DNA copy number profiles of oncogenes and tumor suppressor genes in chromosomal- and microsatellite-unstable sporadic colorectal carcinomas. J Mol Med (Berl) 85: 293-304. 10.1007/s00109-006-0126-5 [doi].
37. Markova B, Albers C, Breitenbuecher F, Melo JV, Brummendorf TH, et al. (2010) Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway. Oncogene 29: 739-751. onc2009374 [pii];10.1038/onc.2009.374 [doi].
38. Bardi G, Fenger C, Johansson B, Mitelman F, Heim S, (2004) Tumor karyotype predicts clinical outcome in colorectal cancer patients. J Clin Oncol 22: 2623-2634. 10.1200/JCO.2004.11.014 [doi];22/13/2623 [pii].
39. Nielsen KV, Brunner N, (2011) Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 103: 352-353. djq528 [pii];10.1093/jnci/djq528 [doi].